they are starting again with TGA because they feel it should be registered in OSLs home country.
TGA can be a great preparatory and (often) bellweather process to preceed FDA submission, but it costs time, focus and $$. Registering in any jurisdiction should have a robust business case. 'Feeling' a product should be registered in your 'home country' is a poor justification for the use of sh funds, imo.
Ann: OncoSil onboards first patient in PANCOSIL Clinical Trial, page-19
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add OSL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
1.5¢ |
Change
0.002(15.4%) |
Mkt cap ! $56.76M | |||
| Open | High | Low | Value | Volume |
| 1.3¢ | 1.5¢ | 1.3¢ | $76.04K | 5.442M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 450000 | 1.4¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 1.5¢ | 9713598 | 7 |
View Market Depth
| Last trade - 16.10pm 27/09/2024 (20 minute delay) ? |
| OSL (ASX) Chart |